Skip to content
    Real-World Studies

    Referral Patterns and Efficacy Outcomes of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

    Fonseca et alCurr Med Res Opin

    A real-world study combining a physician survey and retrospective chart review evaluated referral pathways and clinical outcomes for commercial chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed/refractory multiple myeloma (RRMM). The study surveyed 17 physicians across private community practices (82.4%) and academic centers (17.6%) and reviewed medical records for 72 adult patients treated with commercial ciltacabtagene autoleucel (cilta-cel) between and . Safety endpoints were not captured in this analysis.
    The physician survey revealed substantial gaps in referral for CAR-T evaluation. Out of 289 CAR-T-eligible patients managed by surveyed physicians over the preceding year, 52.9% of clinicians reported that 31% to 50% of eligible patients were not referred. Primary drivers for referral were treatment efficacy (76.5%) and favorable performance status or low frailty (64.7%). Key barriers to referral included patient choice (52.9%), poor performance status or high frailty (47.1%), comorbidity burden (41.2%), and older age (41.2%).
    Logistical demands were substantial among patients who proceeded to cilta-cel infusion: 55.6% traveled more than 30 miles to a treatment center, and 27.8% relocated temporarily for therapy. Among patients with a recorded response assessment, cilta-cel demonstrated high response rates, with an overall response rate of 95.2% and a complete response rate or better of 60.3%. At a median follow-up of 5.6 months, overall survival was 86.1%, with 43.5% of surviving patients maintaining treatment-free remission.

    Key Takeaways

    • In a real-world cohort of patients receiving commercial ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma, the overall response rate was 95.2%, with 60.3% achieving at least a complete response.
    • At a median follow-up of 5.6 months, 86.1% of cilta-cel recipients remained alive, with 43.5% of survivors maintaining remission off active therapy.
    • A physician survey demonstrated substantial underreferral for CAR-T evaluation, with 52.9% of clinicians reporting that 31% to 50% of eligible patients with relapsed/refractory multiple myeloma were not referred.
    Read the original sourceCurr Med Res Opin